0 Bewertungen0% fanden dieses Dokument nützlich (0 Abstimmungen)
109 Ansichten1 Seite
Captopril lowers blood pressure by specific inhibition of the angiotensin-converting enzyme (ACE) ACE inhibition alters hemodynamics without compensatory reflex tachycardia or changes in cardiac output. A sudden exaggerated hypotensive response may occur within 1-3 h of first dose.
Captopril lowers blood pressure by specific inhibition of the angiotensin-converting enzyme (ACE) ACE inhibition alters hemodynamics without compensatory reflex tachycardia or changes in cardiac output. A sudden exaggerated hypotensive response may occur within 1-3 h of first dose.
Copyright:
Attribution Non-Commercial (BY-NC)
Verfügbare Formate
Als DOC, PDF, TXT herunterladen oder online auf Scribd lesen
Captopril lowers blood pressure by specific inhibition of the angiotensin-converting enzyme (ACE) ACE inhibition alters hemodynamics without compensatory reflex tachycardia or changes in cardiac output. A sudden exaggerated hypotensive response may occur within 1-3 h of first dose.
Copyright:
Attribution Non-Commercial (BY-NC)
Verfügbare Formate
Als DOC, PDF, TXT herunterladen oder online auf Scribd lesen
Drug Name Dosage & Route Action Indication Adverse Effects Contraindication Nursing Responsibility
Lowers blood pressure by
CAPTOPRIL Hypertension Hypertension; in conjunction Angioedema, hypersensitivity specific inhibition of the Body as a Whole: Assessment & Drug Effects (kap'toe-pril) Adult: PO 6.25–25 mg with digitalis and diuretics in to captopril or ACE angiotensin-converting Hypersensitivity reactions, t.i.d., may increase to CHF, diabetic nephropathy. inhibitors; hypotension; enzyme (ACE). This serum sickness-like reaction, 50 mg t.i.d. (max: 450 pregnancy (category D), • Monitor BP closely Capoten interrupts conversion arthralgia, skin eruptions. CV: mg/d) lactation. following the first dose. A sequences initiated by renin Slight increase in heart rate, Child: PO 0.3–12.5 sudden exaggerated Classifications: that lead to formation of first dose hypotension, mg/kg q12–24h, may hypotensive response may cardiovascular agent; angiotensin II, a potent dizziness, fainting. GI: titrate up to max of 6 occur within 1–3 h of first angiotensin-converting endogenous vasoconstrictor. Altered taste sensation (loss mg/kg/d in 2–4 dose, especially in those enzyme (ace) inhibitor; ACE inhibition alters of taste perception, persistent divided doses with high BP or on a diuretic antihypertensive agent hemodynamics without salt or metallic taste); weight Infant: PO 0.15–0.3 and restricted salt intake. compensatory reflex loss, intestinal angioedema. mg/kg, may titrate up to 6 mg/kg/d in 1–4 tachycardia or changes in Hematologic: Hyperkalemia, • Advise bed rest and BP cardiac output (except in neutropenia, agranulocytosis monitoring for the first 3 h divided doses patients with CHF). (rare). Respiratory: cough. after the initial dose. Neonate: PO 0.05–0.1 Peripheral vascular resistance Skin: Maculopapular rash, mg/kg q8–24 h, may is lowered by vasodilation. urticaria, pruritus, • Monitor therapeutic titrate up to 0.5 mg/kg effectiveness. At least 2 wk Inhibition of ACE also leads angioedema, photosensitivity. q6–24 h of therapy may be required to decreased circulating Urogenital: Azotemia, Premature infant: PO before full therapeutic aldosterone. Reduced impaired renal function, 0.01 mg/kg q8–12h effects are achieved. circulating aldosterone is nephrotic syndrome, associated with a potassium- membranous • Lab tests: Establish baseline Congestive Heart urinary protein levels before sparing effect. In heart glomerulonephritis. Other: Failure initiation of therapy and failure, captopril Positive antinuclear antibody Adult: PO 6.25–12.5 check at monthly intervals administration is followed by (ANA) titers. mg t.i.d., may increase for the first 8 mo of a fall in CVP and pulmonary to 50 mg t.i.d. (max: treatment and then wedge pressure; hypotensive 450 mg/d) periodically thereafter. action appears to be unrelated to plasma renin levels. Perform WBC and differential counts before therapy is begun and at approximately 2-wk intervals for the first 3 mo of therapy and then periodically thereafter.